Table 2 Correlation of rheumatoid factor and anti-cyclic citrullinated peptide antibodies with patient characteristics at baseline (week 0)

Sex (0 = male, 1 = female)

−0.157

0.0057

−0.043

0.4489

Age

0.154

0.0070

0.106

0.0643

BMI

0.037

0.5141

0.016

0.7863

Disease duration

0.119

0.0368

−0.046

0.4225

NSAID use^a

−0.006

0.9119

0.022

0.7021

Glucocorticoid use^a

0.022

0.6967

0.023

0.6893

DMARD (other than MTX) use^a

−0.051

0.3727

0.065

0.2549

Duration of MTX use

0.050

0.3832

0.009

0.8687

MTX dose

−0.069

0.2256

−0.013

0.8184

Comorbidity^a

−0.023

0.6874

0.129

0.0240

DAS28-CRP

0.087

0.1278

0.042

0.4596

Total modified Sharp score

0.132

0.0214

−0.019

0.7385

HAQ

0.089

0.1186

0.081

0.1557

MMP-3

−0.129

0.0236

−0.057

0.3198

IL-6

0.069

0.2287

0.040

0.4809

TNF

0.209

0.0002

0.117

0.0413

RF

–

–

0.373

<0.0001

Anti-CCP

0.373

<0.0001

–

–